Compared whether the oral combination of an SGLT2 inhibitor (DAPA) and a DPP4 inhibitor (SAXA) could achieve similar glycemic control to basal insulin in T2DM patients poorly controlled with metformin, without causing an increase in hypoglycemia or body weight. This evidence concerns the gene SLC5A2 and Hypoglycemia.